
Sign up to save your podcasts
Or


In this episode, Dr. Cohen sits down with Dr. Mark Edney, Medical Director at Peninsula Institute for Laparoscopic and Robotic Surgery to discuss the limitations of relying on clinical pathology alone and how the addition of Prolaris allows providers to truly understand how a patient's tumor is behaving on a biological level. Dr, Edney also talks about his personal use of biomarkers in his practice and why he believes there is a slow adoption rate of molecular tests in the Urology space. Familial cancer screening and use of hereditary cancer testing to further personalize prostate cancer treatment is also discussed
Send us a text
By Myriad Genetics4.6
1010 ratings
In this episode, Dr. Cohen sits down with Dr. Mark Edney, Medical Director at Peninsula Institute for Laparoscopic and Robotic Surgery to discuss the limitations of relying on clinical pathology alone and how the addition of Prolaris allows providers to truly understand how a patient's tumor is behaving on a biological level. Dr, Edney also talks about his personal use of biomarkers in his practice and why he believes there is a slow adoption rate of molecular tests in the Urology space. Familial cancer screening and use of hereditary cancer testing to further personalize prostate cancer treatment is also discussed
Send us a text